Verapamil, a drug widely used to treat cardiovascular disorders and an important water pollutant, has been subjected for the first time to advanced oxidation by air non-thermal plasma (NTP) in a previously described DBD reactor. Product analysis was performed to assess the extent of mineralization to CO₂, quantified by FT-IR analysis, and to detect and identify oxidation intermediates by LC/ESI-MS/MS. Many intermediates form and their time profile was monitored during the treatment. Thorough mass spectrometric analysis and comparison with literature data on the oxidation of the functional groups of verapamil by the reactive species present in the air plasma allowed us to identify most of the intermediates formed by non-thermal plasma activation. The majority of the identified compounds can be attributed to reactions of verapamil with ozone, one of the major oxidizing species in our DBD reactor. A few intermediates, though, appear to form following direct attack by hydroxyl radicals, whereas there is no evidence of any byproduct attributable to reaction with reactive nitrogen species. When treated at low initial concentration verapamil is almost completely mineralized (98%), as determined by total carbon analysis.

维拉帕米（一种广泛用于治疗心血管疾病和重要水污染物的药物）已在先前描述的DBD反应器中首次通过空气非热等离子体（NTP）进行了高级氧化。进行产品分析以评估成矿到CO ₂的程度，通过FT-IR分析进行定量，并通过LC / ESI-MS / MS检测和鉴定氧化中间体。在处理过程中会监视许多中间体的形式，并监测其时间分布。彻底的质谱分析以及与维拉帕米官能团被空气等离子体中存在的反应性物种氧化的文献数据进行比较后，我们得以鉴定出大多数由非热等离子体活化形成的中间体。鉴定出的大多数化合物可归因于维拉帕米与臭氧的反应，臭氧是我们DBD反应器中的主要氧化物质之一。但是，一些中间体似乎是在被羟基自由基直接攻击后形成的，而没有证据表明任何副产物可归因于与活性氮物质的反应。